

TICH-3 NEWSLETTER

ISRCTN: 97695350 November 2024, Issue 13



TICH-3@nottingham.ac.uk



<http://tich-3.ac.uk/>

Useful documents: [Click here for TICH-3 documents page](#)

Congratulations on the last months recruitment

- 4 UCLH
- 3 Craigavon Area Hospital
- 2 University Hospital of North Durham
- 2 Aberdeen Royal Infirmary
- 2 James Cook University Hospital
- 2 Antrim Area Hospital"
- 2 Aintree University Hospital
- 1 Queens Medical Centre
- 1 Charing Cross Hospital
- 1 Royal Infirmary of Edinburgh
- 1 Royal London Hospital
- 1 Salford Royal Hospital
- 1 Dorset County Hospital
- 1 Addenbrooke's Hospital
- 1 Arrow Park Hospital
- 1 Leeds General Infirmary
- 1 New Cross Hospital
- 1 Morrision Hospital
- 1 Hull Royal Infirmary
- 1 Royal Preston Hospital
- 1 Darent Valley Hospital
- 1 King's Mill Hospital
- 1 Southmead Hospital"
- 1 Royal Bournemouth Hospital


RECRUITMENT UPDATE

Combined total

1303

International total

529



774
UK Participants

TICH-3 has recruited a further 141 UK participants since the last newsletter, 12/07/2024 thank you so much for your continued support!

WELCOME TO TICH-3!



Whiston Hospital, Altnagelvin Hospital, Cumberland Infirmary, Derriford Hospital and Royal Bournemouth Hospital – and well done on your first recruit 8 days after greenlight!

We now have **78 UK sites** open to recruitment for the TICH-3 trial!

TRIAL DOCUMENTS UPDATES

These are not ethically approved documents and therefore there are not any approvals to coincide with this update.

- **UPDATED:** [TICH-3 poster for ED Final v2.2 22.10.2024](#)

This poster is for the emergency department colleagues who aren't on the TICH-3 delegation log to help identify potential participants. They can assess eligibility and contact the research team if participant is eligible or if no-one from the research team is available, they can use the eligibility checklist and enrolment form to enrol the participant themselves.

- **NEW:** [TICH-3 Clinic Poster Final v1.0 22.10.2024](#)

The intention of this poster is to be displayed in the clinic areas to remind the research team members the process to recruit participants into TICH-3.

TRAINING FOR NEW TEAM MEMBERS

New team members can read the appropriate slides for their role

[Click here for link to TICH-3 documents page](#)


Please then complete self-referral form to be added to the online delegation log

[Click here for link to TICH-3 self-referral form](#)



The University of
Nottingham

UNITED KINGDOM · CHINA · MALAYSIA



PAYMENTS

As previously informed the university has now begun a significant IT update as Unicore is to be implemented. Therefore, unfortunately no payments can be processed between 15th October to 20th November. Please can any invoices be submitted from 20th November onwards.

SEIZURES

If the patient is having a seizure at the time they present they are not eligible to be enrolled in the trial. If the participant starts having a seizure during the treatment, please stop the treatment immediately and treat the participant as clinically required. Please then report this as a safety event through the SAE form on the TICH-3 website.



VENOUS THROMBOEMBOLISM (VTE)

Venous thromboembolism (VTE) includes both deep-vein thrombosis (DVT) and pulmonary embolism (PE). VTE is a relative contra-indication for tranexamic acid, enrolment is at the discretion of the treating physician. If a patient had a previous VTE over 3 months ago they can be enrolled into TICH-3 providing they meet the other eligibility criteria.

TARGET PATIENTS MOST LIKELY TO BENEFIT

Please remember we want to target participants that are most likely to benefit from treatment intervention. Patients at the greatest risk are

- If they present very early after the onset of symptoms
- Larger haemotoma volumes
- On antiplatelet therapy or anticoagulants
- CT markers of haemotoma expansion such as black hole or blend sign

<https://doi.org/10.1161/STROKEAHA.119.026128>



TRAINING SESSION: please join us over MS team Thursday 21st November 12.20 – 1.30pm for training on targeting patients most likely to benefit [Join the meeting here](#)

BP LOWERING



Standard of care should be delivered for all trial participants, so please commence blood pressure lowering treatment if clinically indicated. Aiming for a target of BP < 140mmHg as per clinical guidelines, supported by the recent INTERACT -3 Results [https://doi.org/10.1016/S0140-6736\(23\)00806-1](https://doi.org/10.1016/S0140-6736(23)00806-1). There was a synergistic effect in TICH-2 with BP.

KEEPING IN TOUCH AND UPDATE MEETINGS

We would like to invite you all to join the TICH-3 trial team where we will discuss topics of interest for the trial:

- **Wednesday 15th January 12.30 – 1.30pm** [Join the meeting here](#)

Invitations will also have been sent to your email address so look out for these!

If you have any points you would like to discuss, please email the team and we will add them to the meeting.

You can find us on Twitter: [@tich3trial](#) and [@UoN_STU](#)

Please feel free to tweet us or tag us in your Stroke related tweets

[Conferences coming up](#)

Please come and say hi if you are attending the conference, find us at stand A16

- UK Stroke Forum (UKSF) Liverpool, 3 – 5th December 2024
 - TICH-3 investigator meeting Wednesday 4th December 10.40 – 11.25am in room 12, tea and coffee will be provided

